# A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

> **NCT00000391** · PHASE1 · COMPLETED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 30 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Peptide T

## Key facts

- **NCT ID:** NCT00000391
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1988-01
- **Primary completion:** 1990-01
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000391, "A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00000391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*